Citrus-Bergamot

Citrus bergamot extract, derived from the juice and albedo of the bergamot orange (Citrus bergamia Risso & Poiteau), is a polyphenol-rich botanical preparation whose pharmacological interest centers on a distinctive flavonoid profile that includes the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanone glycosides brutieridin and melitidin, alongside high concentrations of neoeriocitrin, naringin, and neohesperidin. These HMG-bearing flavanones are structurally analogous to the HMG-CoA substrate of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis and the molecular target of statin drugs. In vitro mechanistic studies in HepG2 and Caco-2 cell lines have demonstrated that bergamot polyphenolic fraction (BPF) and its principal constituents reduce HMGCR protein levels, activate AMP-activated protein kinase (AMPK) phosphorylation, stimulate fatty acid oxidation, and inhibit intestinal cholesterol absorption through downregulation of the Niemann-Pick C1-Like 1 (NPC1L1) transporter. The mechanism is therefore distinct from direct competitive HMGCR inhibition by statins and involves transcriptional and post-translational regulation of cholesterol biosynthetic and absorptive pathways.

Clinical investigation of bergamot polyphenolic extracts has been conducted primarily in Southern Italian populations with hyperlipidemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). In the pivotal Mollace et al. (2011) open-label study of 237 patients with moderate hypercholesterolemia, BPF at 500 mg or 1000 mg for 30 days reduced total cholesterol by 22 to 31 percent, low-density lipoprotein cholesterol (LDL-C) by 24 to 36 percent, and triglycerides by 28 to 41 percent, while increasing high-density lipoprotein cholesterol (HDL-C) by 22 to 40 percent. Subsequent randomized, double-blind, placebo-controlled trials have confirmed statistically significant reductions in LDL-C and triglycerides at doses of 500 to 1300 mg over 6 to 24 weeks, with concurrent improvements in fasting glucose, HOMA-IR insulin resistance index, and hepatic steatosis markers. A 2020 randomized trial of a bergamot-cardoon combination (Bergacyn) in NAFLD patients over 50 years demonstrated significant reductions in liver steatosis, body weight, and hepatic transaminases.

The pharmacokinetic profile of bergamot flavonoids in humans is incompletely characterized. Oral consumption produces circulating phase II conjugated metabolites (sulfates and glucuronides of naringenin, hesperetin, and eriodictyol) detectable at 1 and 4 hours post-ingestion, consistent with intestinal deglycosylation and hepatic phase II conjugation. The characteristic HMG-conjugated flavanones brutieridin and melitidin have not been detected in plasma or urine in published pharmacokinetic studies, raising the possibility that their hypolipidemic activity is mediated locally in the gastrointestinal epithelium or through metabolites not yet characterized. The extract is generally well tolerated in clinical studies of up to 24 weeks duration, with adverse events limited to mild gastrointestinal discomfort in a minority of subjects. Bergamot contains furanocoumarins (bergamottin, bergapten) that inhibit CYP3A4, producing clinically relevant interactions with statins metabolized by this isoform (atorvastatin, simvastatin, lovastatin) and other CYP3A4 substrates. This monograph reviews the botanical identification, phytochemistry, and standardization of bergamot extract; the molecular pharmacology of its principal flavonoid constituents; the pharmacokinetic record; the preclinical and clinical evidence base across dyslipidemia, metabolic syndrome, NAFLD, and glycemic endpoints; sourcing and quality verification; handling considerations; stack interactions; adverse-event signal; and a comparative assessment of five alternative lipid-modifying nutraceuticals (red yeast rice, berberine, plant sterols/stanols, niacin, and artichoke leaf extract) against citrus bergamot on five competency standards.